The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Patients with schizophrenia often fail to respond to an initial course of therapy. This study systematically reviewed the societal and economic burden of treatment-resistant schizophrenia (TRS). Studies that described patients with TRS published 1996-2012 were included if they collected primary data on clinical, social, or economic outcomes. All studies were independently reviewed and extracted by at least two investigators. Sixty-five studies were identified. Almost 60% (SD 18%) of patients failed to achieve response after 23 weeks on antipsychotic drug therapy. Patients with TRS had high rates of smoking (56%), alcohol abuse (51%), substance abuse (51%), and suicide ideation (44%). The incidence of severe adverse events to treatment was 4% (SD 7%). Mean quality of life for patients who were unresponsive or intolerant to treatment was ∼20% lower than that of patients in remission. Annual costs for patients with schizophrenia are $15 500-$22 300 and are 3-11-fold higher for patients with TRS. TRS remains common and costly, despite availability of many treatment options, and contributes to a significant loss in patient quality of life. Although estimates in the literature vary greatly, TRS conservatively adds more than $34 billion in annual direct medical costs in the USA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the USA, annual direct medical costs associated with TRS are conservatively estimated at over $34 billion. 41”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [41]
In the citing paper
“the mean quality of life is estimated to be 20% lower in TRS compared with non-TRS. 41 Mean quality of life is approximately 25-40% lower in patients with TRD compared with patients who respond to treatment or who are in remission; 46”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [41]
In the citing paper
“It has been estimated that hospitalisation costs and total health resource utilisations for TRS are 10-fold higher than those for non-TRS and that up to 80% of the total yearly health costs associated with schizophrenia in the USA are attributed to TRS. 41”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [41]
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · cited 6×
“In addition, 20–30% fail to respond to treatment, and a similar fraction of treatmentadherent patients relapse despite sustained maintenance therapy (Kane et al., 1988, 2007; Conley and Kelly, 2001).”
BackgroundInfluentialSchizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280 · cited 2×
“…with schizophrenia are more than twice those in the general population, and life expectancy is 12–15 years shorter than that of the general population, often as a result of personal neglect, poverty, and suicide (Barbato, 1998; Mcgrath et al., 2008; Van Os and Kapur, 2009; Wahlbeck et al., 2011).”
BackgroundRoom, R., Babor, T., & Rehm, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17870-2 · Cited by 1,625
Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K., Isometsä, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppä, T., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.19 · Cited by 1,516 · cited 1×
“3% (Perala et al., 2007).”
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105 · cited 2×
“…be indicative of the TR population (Table 6) (Wyatt et al., 1995; Blieden et al., 1998; Percudani et al., 1999; Mccombs et al., 2000; Fuller et al., 2002; Wu et al., 2005; Jones et al., 2006; Ascher-Svanum et al., 2008; Ascher-Svanum et al., 2010; Nicholl et al., 2010; Peng et al., 2011a, 2011b).”
BackgroundDeterminants of Medication Compliance in Schizophrenia: Empirical and Clinical Findings
Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.637 · Cited by 957 · cited 1×
“Patient noncompliance almost certainly contributes to treatment nonresponse in schizophrenia, as better drug adherence is associated with a better prognosis and outcomes (Fenton et al., 1997; Jaeger et al., 2012).”
BackgroundMarwaha, S., & Johnson, S. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0762-4 · Cited by 922
Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders
Wahlbeck, K., Westman, J., Nordentoft, M., Gissler, M., & Laursen, T. M. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.085100 · Cited by 623 · cited 2×
“…with schizophrenia are more than twice those in the general population, and life expectancy is 12–15 years shorter than that of the general population, often as a result of personal neglect, poverty, and suicide (Barbato, 1998; Mcgrath et al., 2008; Van Os and Kapur, 2009; Wahlbeck et al., 2011).”
BackgroundThe Economic Burden of Schizophrenia in the United States in 2002
Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614 · cited 3×
“…be indicative of the TR population (Table 6) (Wyatt et al., 1995; Blieden et al., 1998; Percudani et al., 1999; Mccombs et al., 2000; Fuller et al., 2002; Wu et al., 2005; Jones et al., 2006; Ascher-Svanum et al., 2008; Ascher-Svanum et al., 2010; Nicholl et al., 2010; Peng et al., 2011a, 2011b).”
BackgroundHealth, United States, 2010; with special feature on death and dying
Bernstein, A. B., Bilheimer, L. T., & Makuc, D. M. (2011) · Cited by 498
Cited by
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Fregni, F., El-Hagrassy, M. M., Pacheco-Barrios, K., Carvalho, S., Leite, J., Simis, M., Brunelin, J., Nakamura-Palacios, E. M., Marangolo, P., Venkatasubramanian, G., et al. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa051 · Cited by 605
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives
Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N., & Sawa, A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.016 · Cited by 304
Siskind, D., Orr, S., Sinha, S., Yu, O., Brijball, B., Warren, N., MacCabe, J. H., Smart, S. E., & Kisely, S. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.61 · Cited by 255
“2 These cases of treatment-resistant schizophrenia (TRS) are associated with high levels of functional impairment, 3 healthcare usage, societal costs 4 and physical health comorbidity.”
Metadata
- Authors
- Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C.
- Affiliations
- University of Toronto (CA)
- Stanford Medicine (US)
- Corresponding author
- Hornberger, John C.
- Venue
- International Clinical Psychopharmacology
- Published
- 2014-03
- Volume
- 29
- Issue
- 2
- Pages
- 63-76
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2036480935
- Cited by
- 392
- References
- 84
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 44 · 2023: 39 · 2022: 37 · 2021: 33 · 2020: 35 · 2019: 38 · 2018: 35 · 2017: 16 · 2016: 21 · 2015: 18 · 2014: 6
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant schizophrenia, economic burden, social burden, antipsychotic treatment response, treatment intolerance, smoking, alcohol abuse, substance abuse, suicidal ideation, adverse drug reactions, quality of life, health care costs, direct costs
- MeSH terms
- Costs and Cost Analysis, Drug Resistance, Humans, Psychiatric Status Rating Scales, Quality of Life, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. https://app.cochat.ai/papers/10.1097/yic.0b013e32836508e6
- The paper
- Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014). The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e32836508e6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.